We will hold individual interviews of HLBS patients, including a range of racial, ethnic, and socioeconomic perspectives, to discuss current and future Artificial Intelligence/Big Data technologies. Participants will be recruited from University of Arizona affiliated clinical practices or online, offering $25 each for participation in 60-minute discussions, either by phone or video conference
A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT)
Your child is invited to participate because your child has a peanut allergy. The study will last up to 72 weeks where you will take daily study drug, monthly study injections, complete study questionnaires/diaries, food challenge, skin prick tests, breathing tests, and have your blood drawn.
For Dupilumab there are common risks such as: conjunctivitis (pink eye), injection site reaction (swelling, redness, etc.), your child may experience a local or generalized allergic reaction (also known as a hypersensitivity reaction).
A double blinded four year study for children 24 - 47 months with the goal of identifying if injections of Omalizumab (Xolair) for two years, could prevent children from getting Asthma and lessen the severety of their breathing problems as they grow.
This research is being done to see if a medicine used to treat high blood pressure, Losartan, can slow the damage to the lungs in people who have COPD with emphysema. Currently, there are some medications for COPD to reduce symptoms and prevent exacerbations. However, there are no treatments to slow or stop the progression of the disease.
The Oral Bacterial Extract (ORBEX) Study is a three year study to see whether the wheezing and lower respiratory tract illnesses that lead to asthma can be prevented. The goal is to find if a medication that is used in Europe, called Broncho-Vaxom®, can prevent wheezing lower respiratory infections in young children. It may work to stimulate a child’s immune system in order to increase the body’s defenses against germs that cause children to have respiratory illnesses.